Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022

October 26th 2022

Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.

Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab

October 26th 2022

Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.

Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

October 24th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the future implications of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer.

Mitomycin C Reduces the Number of Procedures Following NMIBC Recurrence

October 21st 2022

Chemoresection with mitomycin C, a nonsurgical treatment modality, significantly reduced the need for transurethral resection of bladder tumors or office biopsy and tumor fulguration following recurrence in patients with recurrent nonmuscle invasive bladder cancer.

Rogaratinib Is Noninferior to Chemo in Pretreated FGFR1/3 mRNA+ Locally Advanced or Metastatic Urothelial Carcinoma

October 19th 2022

Rogaratinib induced an objective response rate similar to that of chemotherapy in patients with FGFR1/3 mRNA–positive locally advanced or metastatic urothelial carcinoma who have received at least 1 prior platinum-containing chemotherapy.

Outcomes of the JAVELIN Bladder 100 Trial

October 19th 2022

Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.

Treatment Options for Frontline Metastatic Urothelial Carcinoma

October 19th 2022

Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.

Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer

October 18th 2022

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

An Influx of Data Expands Options, Improves Treatment for Bladder Cancer

October 18th 2022

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Standards of Care Shift Toward Patient Specificities in Bladder and Prostate Cancers

October 13th 2022

Shilpa Gupta, MD, discussed potential therapies for patients with cisplatin-ineligible metastatic urothelial carcinoma, the benefits of sacituzumab govitecan and erdafitinib in later-line urothelial carcinoma, and treatment options for nonmetastatic castration-resistant prostate cancer.

Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study

October 13th 2022

Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.

Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial

October 12th 2022

Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.

Frontline Avelumab Maintenance Displays Long-Term Benefit in Advanced Urothelial Carcinoma

October 10th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the results of the subgroup analysis in patients with urothelial carcinoma who received frontline avelumab maintenance for at least 12 months on the phase 3 JAVELIN Bladder 100 trial.

Neoadjuvant Radioimmunotherapy Demonstrates Feasibility in Locally Advanced Urothelial Carcinoma

October 7th 2022

Sebastian C. Schmid, MD, discusses the results of the RACE IT trial, what the data mean for patients with locally advanced urothelial carcinoma, and the next steps for researching neoadjuvant radioimmunotherapy in this patient population.

Sonpavde Reviews Urothelial Carcinoma Treatment Highlights from ESMO 2022

October 6th 2022

Guru P. Sonpavde, MD, provides commentary on several studies in urothelial carcinoma and how data presented at ESMO may affect clinical practice.

Dr. Desai on Immune Checkpoint Inhibitors with Chemoradiation in Urothelial Cancer

October 5th 2022

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Pembrolizumab Improves Outcomes Regardless of Response to Prior Chemotherapy in Advanced Urothelial Cancer

October 5th 2022

Response to pembrolizumab monotherapy was observed regardless of prior response to chemotherapy in patients with advanced urothelial cancer.

Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma

October 5th 2022

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

Incidence and Risk Factors for Urothelial Carcinoma

October 5th 2022

Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.

Dr. Zhang on Multidisciplinary Approaches in Urothelial Cancer

September 30th 2022

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.